Home › Psychological Burnout › NCT06814522
Psilocybin-Assisted Therapy for Physician Well-Being and Burnout
Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)]
Who can join
Ages 21 to 70 · All sexes
Full eligibility criteria
Inclusion Criteria: 1. Faculty physician, aged 21-70. Volunteer faculty are not included 2. Meets criteria for physician burnout 3. Experiencing symptoms of burnout for \>6 months 4. Able to complete all required study visits 5. Not previously diagnosed with a serious mental illness (including schizophrenia, bipolar disorder, and severe depression), or substance use disorder as confirmed in clinical interview 6. Not currently taking any psychotropic medications or nonpsychotropic medication that may be associated with serotonin syndrome, such as serotonin reuptake inhibitors (SSRI or SNRI), dextromethorphan, linezolid, tramadol, meperidine Exclusion Criteria: 1. Previous inpatient psychiatric hospitalization(s) 2. Previously diagnosed with a psychotic disorder (schizophrenia, schizoaffective disorder, or other psychotic spectrum disorder), bipolar spectrum disorder, personality disorder (borderline personality disorder, antisocial personality disorder, or other severe personality disorders), any severe psychiatric disorder. 3. Exhibiting elevated suicide risk 4. First degree family history of psychosis or bipolar disorder 5. Prior exposure to psilocybin or other psychedelic compounds in the previous 5 years 6. Currently pregnant, nursing, planning pregnancy, engaging in sexual intercourse without effective contraceptive method in last three months 7. Those who plan to donate sperm within three months following the study. 8. Known cardiovascular disease including history of stroke, myocardial infarction, uncontrolled hypertension, valvular heart disease, tachycardia, elongated QT interval, or clinically significant arrythmia. 9. History of seizure disorder 10. Use of recreational illicit drugs 11. Clinically concerning results from vital signs, ECG, physical examination, or laboratory tests during screening 12. Any other clinically significant illnesses deemed to pose risk for the participant
About the study
Through an open-label study involving a small group of UCSD physicians experiencing burnout, the investigators will evaluate the feasibility, safety, and preliminary effectiveness of PAT to reduce burnout symptoms.
What is being tested
- Psilocybin, [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate (drug)
- Real-time Biofeedback (device)
Sponsor: University of California, San Diego · Participants: 30 · Started: Jan 13, 2025
Contact the study team
- Vy Nguyen · Phone: 619-363-2465
Official record on ClinicalTrials.gov — NCT06814522
Locations in the U.S.
| California | UC San Diego, San Diego |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.